Is JSPR or ENTX more profitable?

Entera Bio's return on equity of -83.31% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% Entera Bio N/A -83.31% -70.83%

Does the media refer more to JSPR or ENTX?

In the previous week, Entera Bio had 5 more articles in the media than Jasper Therapeutics. MarketBeat recorded 6 mentions for Entera Bio and 1 mentions for Jasper Therapeutics. Entera Bio's average media sentiment score of 0.14 beat Jasper Therapeutics' score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entera Bio 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AADI or JSPR?

Jasper Therapeutics has a consensus price target of $12.00, indicating a potential upside of 1,804.76%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Does the media favor VRCA or JSPR?

In the previous week, Verrica Pharmaceuticals had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.00 beat Verrica Pharmaceuticals' score of -0.02 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SXTC or JSPR?

Jasper Therapeutics has a consensus price target of $12.00, indicating a potential upside of 1,804.76%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than China SXT Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has higher valuation & earnings, SXTC or JSPR?

China SXT Pharmaceuticals has higher revenue and earnings than Jasper Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 2.07 -$6.20M N/A N/A Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A

Is SXTC or JSPR more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets China SXT Pharmaceuticals N/A N/A N/A Jasper Therapeutics N/A -613.51% -162.52%

Which has preferable earnings & valuation, BMEA or JSPR?

Biomea Fusion is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.68 N/A Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A

Is BMEA or JSPR more profitable?

Biomea Fusion's return on equity of -265.37% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Jasper Therapeutics N/A -613.51% -162.52%

Does the media prefer BMEA or JSPR?

In the previous week, Biomea Fusion and Biomea Fusion both had 1 articles in the media. Biomea Fusion's average media sentiment score of 0.00 equaled Jasper Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Jasper Therapeutics (JSPR) Competitors

$0.63 +0.01 (+1.48%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.63 +0.00 (+0.16%)

As of 07/31/2026 07:42 PM Eastern

Compare

JSPR vs. ENTX, AADI, VRCA, SXTC, and BMEA

Should you buy Jasper Therapeutics stock or one of its competitors? MarketBeat compares Jasper Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jasper Therapeutics include Entera Bio (ENTX), Aadi Bioscience (AADI), Verrica Pharmaceuticals (VRCA), China SXT Pharmaceuticals (SXTC), and Biomea Fusion (BMEA).

How does Jasper Therapeutics compare to Entera Bio?

Jasper Therapeutics (NASDAQ:JSPR) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Jasper Therapeutics has a beta of 3.07, meaning that its share price is 207% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

Jasper Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 1,804.76%. Entera Bio has a consensus price target of $9.00, suggesting a potential upside of 201.00%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Entera Bio has higher revenue and earnings than Jasper Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
Entera Bio	$40K	3,684.43	-$11.44M	-$0.27	N/A

Entera Bio's return on equity of -83.31% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
Entera Bio	N/A	-83.31%	-70.83%

In the previous week, Entera Bio had 5 more articles in the media than Jasper Therapeutics. MarketBeat recorded 6 mentions for Entera Bio and 1 mentions for Jasper Therapeutics. Entera Bio's average media sentiment score of 0.14 beat Jasper Therapeutics' score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entera Bio	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 10.6% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Entera Bio beats Jasper Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.07, meaning that its share price is 207% more volatile than the broader market.

Aadi Bioscience has higher revenue and earnings than Jasper Therapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.79	-$65.76M	-$2.35	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

Jasper Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Jasper Therapeutics	N/A	-613.51%	-162.52%

In the previous week, Jasper Therapeutics had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 1 mentions for Jasper Therapeutics and 0 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.00 equaled Jasper Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Jasper Therapeutics	Neutral

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Comparatively, 2.3% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Jasper Therapeutics has a consensus price target of $12.00, indicating a potential upside of 1,804.76%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Jasper Therapeutics beats Aadi Bioscience on 8 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Verrica Pharmaceuticals has higher revenue and earnings than Jasper Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.52	-$17.89M	-$1.03	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

Verrica Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.07, meaning that its stock price is 207% more volatile than the broader market.

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 2.3% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Verrica Pharmaceuticals had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.00 beat Verrica Pharmaceuticals' score of -0.02 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verrica Pharmaceuticals presently has a consensus price target of $14.50, suggesting a potential upside of 177.78%. Jasper Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 1,804.76%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Jasper Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Jasper Therapeutics' return on equity of -613.51% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Jasper Therapeutics	N/A	-613.51%	-162.52%

Summary

Jasper Therapeutics beats Verrica Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Jasper Therapeutics compare to China SXT Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

China SXT Pharmaceuticals' return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Jasper Therapeutics	N/A	-613.51%	-162.52%

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 2.3% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

China SXT Pharmaceuticals has higher revenue and earnings than Jasper Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	2.07	-$6.20M	N/A	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

China SXT Pharmaceuticals has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.07, indicating that its stock price is 207% more volatile than the broader market.

Jasper Therapeutics has a consensus price target of $12.00, indicating a potential upside of 1,804.76%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Jasper Therapeutics had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 1 mentions for Jasper Therapeutics and 0 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.00 equaled Jasper Therapeutics'average media sentiment score.

Company	Overall Sentiment
China SXT Pharmaceuticals	Neutral
Jasper Therapeutics	Neutral

Summary

Jasper Therapeutics beats China SXT Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Jasper Therapeutics compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Biomea Fusion presently has a consensus target price of $8.50, indicating a potential upside of 626.50%. Jasper Therapeutics has a consensus target price of $12.00, indicating a potential upside of 1,804.76%. Given Jasper Therapeutics' higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Biomea Fusion is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

In the previous week, Biomea Fusion and Biomea Fusion both had 1 articles in the media. Biomea Fusion's average media sentiment score of 0.00 equaled Jasper Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biomea Fusion's return on equity of -265.37% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Jasper Therapeutics	N/A	-613.51%	-162.52%

Biomea Fusion has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.07, suggesting that its share price is 207% more volatile than the broader market.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by company insiders. Comparatively, 2.3% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biomea Fusion beats Jasper Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JSPR vs. The Competition

Export

Metric	Jasper Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.64M	$3.55B	$7.17B	$12.47B
Dividend Yield	N/A	3.78%	2.59%	9.45%
P/E Ratio	-0.20	7.38	282.25	24.66
Price / Sales	N/A	1,275.36	588.73	89.76
Price / Cash	N/A	98.58	71.23	59.99
Price / Book	4.20	16.80	11.09	5.90
Net Income	-$75.80M	-$12.46M	$3.50B	$336.31M
7 Day Performance	-8.48%	-1.47%	-0.24%	0.09%
1 Month Performance	47.09%	-8.45%	-3.70%	-5.17%
1 Year Performance	-78.13%	48.32%	61.98%	18.61%

Jasper Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JSPR Jasper Therapeutics	2.3968 of 5 stars	$0.63 +1.5%	$12.00 +1,804.8%	-78.1%	$17.64M	N/A	N/A	20
ENTX Entera Bio	2.83 of 5 stars	$1.99 +0.5%	$9.00 +352.3%	+53.3%	$97.60M	$40K	N/A	20	News Coverage
AADI Aadi Bioscience	N/A	$3.89 flat	N/A	+120.0%	$96.07M	$25.07M	N/A	40
VRCA Verrica Pharmaceuticals	2.1843 of 5 stars	$5.49 -1.8%	$14.50 +164.1%	-7.4%	$96.03M	$35.58M	N/A	40	News Coverage Upcoming Earnings
SXTC China SXT Pharmaceuticals	0.7768 of 5 stars	$2.43 -0.8%	N/A	-100.0%	$93.63M	$1.14M	N/A	90	Analyst Downgrade Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JSPR) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jasper Therapeutics (JSPR) Competitors

JSPR vs. ENTX, AADI, VRCA, SXTC, and BMEA

How does Jasper Therapeutics compare to Entera Bio?

Summary

How does Jasper Therapeutics compare to Aadi Bioscience?

Summary

How does Jasper Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Jasper Therapeutics compare to China SXT Pharmaceuticals?

Summary

How does Jasper Therapeutics compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jasper Therapeutics (JSPR) Competitors

JSPR vs. ENTX, AADI, VRCA, SXTC, and BMEA

How does Jasper Therapeutics compare to Entera Bio?

Which has more risk & volatility, JSPR or ENTX?

Do analysts rate JSPR or ENTX?

Which has stronger valuation & earnings, JSPR or ENTX?

Is JSPR or ENTX more profitable?

Does the media refer more to JSPR or ENTX?

Do institutionals & insiders hold more shares of JSPR or ENTX?

Summary

How does Jasper Therapeutics compare to Aadi Bioscience?

Which has more risk & volatility, AADI or JSPR?

Which has preferable valuation and earnings, AADI or JSPR?

Is AADI or JSPR more profitable?

Does the media prefer AADI or JSPR?

Do institutionals and insiders have more ownership in AADI or JSPR?

Do analysts prefer AADI or JSPR?

Summary

How does Jasper Therapeutics compare to Verrica Pharmaceuticals?

Which has better valuation & earnings, VRCA or JSPR?

Which has more volatility and risk, VRCA or JSPR?

Do institutionals and insiders have more ownership in VRCA or JSPR?

Does the media favor VRCA or JSPR?

Do analysts prefer VRCA or JSPR?

Is VRCA or JSPR more profitable?

Summary

How does Jasper Therapeutics compare to China SXT Pharmaceuticals?

Is SXTC or JSPR more profitable?

Do insiders & institutionals believe in SXTC or JSPR?

Which has higher valuation & earnings, SXTC or JSPR?

Which has more risk & volatility, SXTC or JSPR?

Do analysts recommend SXTC or JSPR?

Does the media favor SXTC or JSPR?

Summary

How does Jasper Therapeutics compare to Biomea Fusion?

Do analysts rate BMEA or JSPR?

Which has preferable earnings & valuation, BMEA or JSPR?

Does the media prefer BMEA or JSPR?

Is BMEA or JSPR more profitable?

Which has more volatility and risk, BMEA or JSPR?

Do insiders and institutionals believe in BMEA or JSPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools